The Oncology Institute, Inc. (TOIIW) Stock Analysis
DELISTED 2026
What happened to The Oncology Institute, Inc. (TOIIW) stock?
The Oncology Institute, Inc. (TOIIW) no longer trades on public markets. It was delisted in August 2026. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
The Oncology Institute, Inc. (TOIIW) trades at $0.0474. The Oncology Institute, Inc. provides medical oncology services in the United States, including physician services, in-house infusion and dispensary, and clinical trial management. Market cap: $470M, Sector: Healthcare.
Last analyzed: Mar 16, 2026Analyst Coverage for TOIIW: TOIIW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TOIIW against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
TOIIW: the 2 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →The Oncology Institute, Inc. (TOIIW) Healthcare & Pipeline Overview
The Oncology Institute, Inc. (TOIIW) delivers comprehensive medical oncology services in the U.S., including in-house infusion, clinical trials, and patient support. With a focus on outpatient care and clinical trial management, TOIIW operates within the competitive healthcare landscape, marked by a negative P/E ratio of -47.54 and a small-cap valuation.
What Is the Investment Thesis for TOIIW?
The Oncology Institute, Inc. (TOIIW) presents a complex investment case. The company's comprehensive oncology services, including in-house infusion and clinical trial management, offer potential for growth in the expanding cancer care market. However, TOIIW's negative P/E ratio of -47.54 and a negative profit margin of -12.1% indicate financial challenges. The company's low beta of 0.21 suggests lower volatility compared to the broader market. Key growth catalysts include expanding clinical trial services and increasing patient volume. Investors should closely monitor TOIIW's ability to improve profitability and manage operational costs. The company's small market capitalization of $470M also implies higher risk and potential for significant price fluctuations.
Based on FMP financials and quantitative analysis
TOIIW Key Highlights
Market Cap: $0.01B indicates a small-cap company with potential for high growth but also higher risk.
- P/E Ratio: -47.54 reflects negative earnings, suggesting the company is currently not profitable.
- Profit Margin: -12.1% shows the company is spending more than it earns, requiring careful monitoring of cost management.
- Gross Margin: 13.8% indicates the percentage of revenue exceeding the cost of goods sold, reflecting the pricing strategy and production efficiency.
- Beta: 0.21 suggests the stock is significantly less volatile than the market average, potentially offering stability during market downturns.
Who Are TOIIW's Competitors?
TOIIW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALLR Allarity Therapeutics, Inc. | $1.43 | +0.00% | $22.8M | — |
| BCTX BriaCell Therapeutics Corp. | $3.96 | +12.18% | $34.5M | 43 |
| ENTO ENTO | $2.85 | -5.00% | $13.6M | 49 |
| IRIX IRIDEX Corporation | $0.78 | -15.83% | $13.6M | — |
| MCTA Charming Medical Limited Class A Ordinary Shares | $29.36 | +0.00% | $446M | 56 |
| CCRN Cross Country Healthcare, Inc. | $13.25 | +0.00% | $428M | 53 |
| AUNA Auna S.A. | $5.43 | +0.18% | $402M | 53 |
| WHTCF WELL Health Technologies Corp. | $3.26 | +1.88% | $833M | 56 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TOIIW's Key Strengths?
Comprehensive oncology service offerings.
- In-house infusion and dispensary services.
- Clinical trial management expertise.
- Outpatient stem cell transplant capabilities.
What Are TOIIW's Weaknesses?
Negative P/E ratio indicating unprofitability.
- Negative profit margin reflecting financial challenges.
- Small market capitalization increasing volatility.
- Limited geographic presence within the United States.
What Could Drive TOIIW Stock Higher?
Expansion of clinical trial programs attracting pharmaceutical partnerships.
- Potential regulatory approvals for new cancer treatments.
- Increasing patient volume due to demographic trends.
- Strategic partnerships with healthcare providers to expand geographic reach.
What Are the Key Risks for TOIIW?
Financial-distress signal — its Altman Z-Score of 0.78 sits in the distress zone (elevated bankruptcy risk).
- Regulatory changes impacting reimbursement rates.
- Competition from established healthcare providers.
- Economic downturn affecting patient access to care.
- Financial instability due to negative profitability metrics.
What Are the Growth Opportunities for TOIIW?
- Expansion of Clinical Trial Services: The Oncology Institute can expand its clinical trial services by partnering with pharmaceutical companies and research institutions. The global clinical trials market is projected to reach $68.8 billion by 2028, growing at a CAGR of 5.7%. TOIIW's management of clinical trials provides a significant growth avenue, attracting revenue from pharmaceutical companies seeking trial sites and patient recruitment. This expansion can be achieved through strategic partnerships and investments in infrastructure to support clinical trial operations, enhancing its competitive position.
- Geographic Expansion within the United States: TOIIW can grow by expanding its facilities and services to new geographic markets within the United States. The demand for oncology services is increasing nationwide, driven by demographic trends and rising cancer incidence rates. By establishing new clinics and treatment centers in underserved areas, TOIIW can capture a larger market share and increase its patient base. This expansion requires careful market analysis and strategic site selection to ensure optimal resource allocation and return on investment. The timeline for this expansion is dependent on securing funding and regulatory approvals.
- Enhancement of Outpatient Stem Cell Transplant Programs: The Oncology Institute can further develop and promote its outpatient stem cell transplant programs. Outpatient stem cell transplants offer convenience and reduced costs compared to inpatient procedures. By investing in advanced technologies and specialized staff, TOIIW can attract more patients seeking this treatment option. The market for stem cell transplants is growing, driven by advancements in transplant techniques and increasing success rates. This initiative can improve patient outcomes and enhance TOIIW's reputation as a leading oncology service provider.
- Development of Palliative Care Programs: TOIIW can expand its palliative care programs to provide comprehensive support for cancer patients and their families. Palliative care focuses on relieving symptoms and improving the quality of life for patients with serious illnesses. By offering specialized palliative care services, TOIIW can address the holistic needs of its patients and differentiate itself from competitors. The demand for palliative care is increasing as healthcare providers recognize the importance of addressing the emotional and psychological well-being of patients. This expansion can be achieved through training programs and partnerships with palliative care specialists.
- Integration of Telehealth Services: The Oncology Institute can integrate telehealth services to improve patient access and convenience. Telehealth allows patients to consult with physicians and receive follow-up care remotely, reducing the need for in-person visits. By investing in telehealth infrastructure and training staff, TOIIW can expand its reach and improve patient satisfaction. The telehealth market is growing rapidly, driven by advancements in technology and increasing acceptance of remote healthcare services. This integration can enhance TOIIW's service offerings and attract patients seeking convenient and accessible care.
What Are TOIIW's Competitive Advantages?
- Integrated Service Model: Offers a comprehensive suite of oncology services under one roof, creating convenience for patients.
- Clinical Trial Expertise: Manages and conducts clinical trials, attracting pharmaceutical partnerships and revenue.
- Established Infrastructure: Operates multiple care facilities with specialized equipment and trained staff.
- Patient-Centric Approach: Focuses on providing personalized care and support to improve patient outcomes.
What Does TOIIW Do?
Founded in 2007 and headquartered in Cerritos, California, The Oncology Institute, Inc. (TOIIW) operates as a medical oncology service provider in the United States. The company offers a range of services, including physician consultations, in-house infusion and dispensary services, management of clinical trials, outpatient stem cell transplants, transfusions programs, and comprehensive patient support. TOIIW manages clinical trials, palliative care programs, and stem cell transplants for cancer patients. Its business model focuses on providing integrated cancer care services, aiming to improve patient outcomes and experiences. The Oncology Institute's services are designed to provide a continuum of care, addressing various needs of cancer patients from diagnosis through treatment and supportive care. The company's geographic focus is within the United States, where it operates multiple care facilities. TOIIW competes with other oncology service providers and healthcare facilities, emphasizing its comprehensive service offerings and patient-centric approach.
What Products and Services Does TOIIW Offer?
- Provides physician services for cancer patients.
- Offers in-house infusion and dispensary services.
- Manages and conducts clinical trials for new cancer treatments.
- Performs outpatient stem cell transplants and transfusions.
- Provides palliative care programs to improve quality of life.
- Offers comprehensive patient support services.
- Manages clinical trials for cancer patients.
How Does TOIIW Make Money?
- Generates revenue through physician services and consultations.
- Earns income from in-house infusion and dispensary services.
- Receives payments for managing and conducting clinical trials.
- Collects fees for outpatient stem cell transplants and transfusions.
What Industry Does TOIIW Operate In?
The Oncology Institute, Inc. operates within the medical care facilities industry, which is part of the broader healthcare sector. This industry is characterized by increasing demand for cancer care services due to an aging population and advancements in cancer treatment. The competitive landscape includes established healthcare providers, specialized oncology centers, and clinical trial organizations. TOIIW differentiates itself through its integrated service model, combining physician services, in-house treatments, and clinical trial management. The industry is subject to regulatory oversight and reimbursement policies, impacting revenue and profitability. Market trends include a shift towards outpatient care and personalized medicine, which TOIIW aims to capitalize on through its service offerings.
Who Are TOIIW's Key Customers?
- Cancer patients seeking medical oncology services.
- Pharmaceutical companies requiring clinical trial management.
- Healthcare providers referring patients for specialized oncology care.
- Patients needing stem cell transplants and transfusions.
Company Profile
The Oncology Institute, Inc. operates in the Medical - Care Facilities industry within the Healthcare sector. It is headquartered in Cerritos, US. The company is led by CEO Daniel Virnich. TOIIW has traded publicly since 2021.
How The Oncology Institute, Inc. Is Valued
The Oncology Institute, Inc. carries a market capitalization of $470M, placing it in the small-cap category.
Key Financial Metrics
Return on equity for The Oncology Institute, Inc. stands at 209.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -20.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -70.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.36 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -74.3%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
The Oncology Institute, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 0.78 places it in the distress zone, a signal of elevated financial risk.
Forward Outlook
Wall Street analysts project The Oncology Institute, Inc. revenue of about $651.8M for fiscal 2026, with EPS near $-0.14. The estimate reflects 5 contributing analysts.
TOIIW Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, signaling potential growth.
- Community sentiment has shifted positively, with discussions highlighting advancements in cancer treatment options.
- The Oncology Institute's focus on expanding its network of clinics is seen as a strategic move to capture a larger market share.
- Increased media attention around oncology innovations has boosted interest in the company, enhancing its visibility among investors.
Bear Case
- Concerns about the competitive landscape in the oncology sector have emerged, with analysts noting potential challenges from larger players.
- Some community members express skepticism regarding the company's ability to scale its operations effectively amid rapid changes in healthcare.
- Recent earnings reports have raised questions about the sustainability of growth, leading to cautious sentiment among investors.
- Potential regulatory hurdles in the healthcare space could impact the company's plans and timelines for expansion.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
TOIIW Latest News
No recent news available for TOIIW.
Leadership: Daniel Virnich
CEO
Daniel Virnich serves as the CEO of The Oncology Institute, Inc., managing a workforce of 825 employees. His background includes extensive experience in healthcare management and operations. Prior to joining The Oncology Institute, he held leadership positions in various healthcare organizations, focusing on strategic planning, financial management, and operational efficiency. He holds advanced degrees in healthcare administration and business management, providing him with a strong foundation for leading a complex healthcare organization.
Track Record: Under Daniel Virnich's leadership, The Oncology Institute has focused on expanding its service offerings and improving patient outcomes. Key achievements include the development of new clinical trial programs and the expansion of outpatient stem cell transplant capabilities. He has also overseen efforts to enhance operational efficiency and improve financial performance. His strategic decisions have aimed to position The Oncology Institute as a leading provider of comprehensive cancer care services in the United States.
Common Questions About TOIIW (Healthcare)
What happened to The Oncology Institute, Inc. (TOIIW) stock?
The Oncology Institute, Inc. (TOIIW) no longer trades on public markets. It was delisted in August 2026. The figures below are historical and are not a current quote.
Can I still buy TOIIW shares?
No. TOIIW stopped trading on public markets in August 2026, so the shares are not available through a broker. Anything you see quoted for TOIIW elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before TOIIW stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to The Oncology Institute, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does The Oncology Institute, Inc. do?
The Oncology Institute, Inc. (TOIIW) provides comprehensive medical oncology services in the United States. This includes physician consultations, in-house infusion and dispensary services, management of clinical trials, outpatient stem cell transplants, transfusions programs, and patient support. The company focuses on delivering integrated cancer care services, aiming to improve patient outcomes and experiences.
What do analysts say about TOIIW stock?
Analyst coverage of The Oncology Institute, Inc. (TOIIW) is limited, reflecting its small market capitalization and financial challenges. Key valuation metrics, such as the negative P/E ratio of -47.54, indicate that the company is currently not profitable. Growth considerations include the potential for expanding clinical trial services and increasing patient volume.
What are the main risks for TOIIW?
The Oncology Institute, Inc. (TOIIW) faces several key risks. Financial risks include the company's negative P/E ratio and profit margin, indicating potential challenges in achieving profitability. Regulatory risks involve changes in reimbursement policies that could impact revenue. Competitive risks include competition from established healthcare providers and specialized oncology centers.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage may affect the accuracy of market sentiment.
- Financial data is based on the most recent filings and may not reflect current performance.